

Sarepta Therapeutics, Inc.
Form 4
September 21, 2016

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Kaye Edward M. MD

(Last) (First) (Middle)

215 FIRST STREET, SUITE 415

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
Sarepta Therapeutics, Inc. [SRPT]

3. Date of Earliest Transaction
(Month/Day/Year)
09/19/2016

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify
below)

President, CEO & CMO

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	09/19/2016		M	(A) or (D) Amount 13,000 (1) A	\$ 8.28 89,983	D	
Common Stock	09/19/2016		S	(A) or (D) Amount 13,000 (1) D	\$ 50 76,983	D	
Common Stock	09/19/2016		M	(A) or (D) Amount 947 (1) A	\$ 5.4 77,930	D	
Common Stock	09/19/2016		S	(A) or (D) Amount 947 (1) D	\$ 50 76,983	D	
Common Stock	09/19/2016		M	(A) or (D) Amount 10,405 (1) A	\$ 5.4 87,388	D	

Edgar Filing: Sarepta Therapeutics, Inc. - Form 4

Common Stock	09/19/2016	S	10,405 ⁽¹⁾	D	\$ 50	76,983	D
--------------	------------	---	-----------------------	---	-------	--------	---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Security (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Options (right to buy)	\$ 13.9	09/19/2016		M		13,000 <u>(1)</u>		06/20/2012	06/20/2012	Common Stock	13,000
Incentive Stock Options (right to buy)	\$ 5.4	09/19/2016		M		947 <u>(1)</u>		04/24/2013	04/24/2022	Common Stock	947
Non-Qualified Stock Options (right to buy)	\$ 5.4	09/19/2016		M		10,405 <u>(1)</u>		04/24/2013	04/24/2022	Common Stock	10,405

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Kaye Edward M. MD 215 FIRST STREET SUITE 415 CAMBRIDGE, MA 02142	X		President, CEO & CMO	

Signatures

/s/David Tyronne Howton, as Attorney-in-Fact for Edward M. Kaye

09/21/2016

Signature of Reporting Person

Date _____

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person, on March 16, 2016, accordingly, the reporting person had no discretion with regards to the timing of the transaction.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.